TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05323201

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fhB7H3.CAR-Ts
Description: fhB7H3.CAR-Ts will be transhepatic arterial infused after lymphodepletion. Three dose levels will be evaluated: Dose Level 1 (1×10\^6/kg), dose Level 2 (3×10\^6/kg) and dose Level 3 (5×10\^6/kg). If dose limiting toxicities (DLTs) are observed in each doses, Dose Level -1 (0.5×10\^6/kg /infusion) will be evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 i.v. for 3 consecutive days (Day -5\~Day -3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 i.v. for once (Day -5)
Study: NCT06545838

Intervention type: OTHER
Intervention: Analysis of plasma renin concentration
Description: The concentration of plasma renin in patients will be assessed using the immunochemiluminescent method
Study: NCT05587439

Intervention type: GENETIC
Intervention: Data and Specimen Collection
Description: * Provide blood and/or saliva sample~* Answer short questionnaires~* Consider consenting to other optional parts of the research such as:~  * use stored tissue samples related to prior cancer treatment~ * Allow access to deceased relatives' medical records and stored specimens~ * Provide blood 1x per year for up to 5 years~ * Provide contact information of family members

Intervention type: GENETIC
Intervention: Data and Specimen Collection
Description: * Provide blood and/or saliva sample~* Answer short questionnaires~* Consider consenting to other optional parts of the research such as:~  * use stored tissue samples related to prior cancer treatment~ * Allow access to deceased relatives' medical records and stored specimens~ * Provide blood 1x per year for up to 5 years~ * Provide contact information of family members

Intervention type: GENETIC
Intervention: Data and Specimen Collection
Description: * Provide blood and/or saliva sample~* Answer short questionnaires~* Consider consenting to other optional parts of the research such as:~  * use stored tissue samples related to prior cancer treatment~ * Allow access to deceased relatives' medical records and stored specimens~ * Provide blood 1x per year for up to 5 years~ * Provide contact information of family members
Study: NCT05685927

Intervention type: DRUG
Intervention: 6-months of medically assisted glycemic improvement
Description: Administrated by the clinic at Steno Diabetes Center, Aarhus, Denmark

Intervention type: DRUG
Intervention: 6-months of medically assisted glycemic improvement
Description: Administrated by the clinic at Steno Diabetes Center, Aarhus, Denmark

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Participants are examined prior to and 1 year following bariatric surgery in the Central Region, Denmark

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Participants are examined prior to and 1 year following bariatric surgery in the Central Region, Denmark
Study: NCT05117164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enteral feeding as per predefined protocol
Description: Infants will receive enteral feeding based on the following protocol.~Enteral nutrition Minimal enteral nutrition (MEN) will begin within 72 hours life at 10 to 20. mL/kg/day, via bolus gravity breast milk/donor human milk. MEN will not be included in the caloric goals.~Advancements in feeding will be set at 20-30 mL/kg/day, but not more than 10ml per feeding portion to reach a goal of 150ml/kg/day, but not than 120ml/kg/day cases of fluid restriction).~The goal will be to reach an overall daily caloric intake of minimum 100kcal/kg/d.
Study: NCT04943367

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TEAS
Description: Transcutaneous electrical acupuncture stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEAS
Description: Transcutaneous electrical acupuncture stimulation
Study: NCT05621603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: The proposed intervention for the school workforce draws on a mental health integrated disaster preparedness model, emphasizing peer support, developed and used successfully by our team working with communities experiencing multiple disasters.~The 3 hour training is comprised of 4 modules - Module 1: Emergency Preparedness Module 2: Psychological Preparedness Module 3: Peer Support Module 4: Shared Leadership and Feedback Session
Study: NCT05788211

Intervention type: OTHER
Intervention: standard of care
Description: retrospective study: standard of care
Study: NCT05373459

Intervention type: BIOLOGICAL
Intervention: Third COVID-19 booster
Description: Third COVID-19 booster
Study: NCT06421610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PITAC
Description: Cisplatin, oxaliplatin and doxorubicin are standard, commercially available intravenous cytostatic drugs in oncologic treatment with alkylating and topoisomerase inhibitor effect, respectively. Based on the available data and experience from 11 PITAC procedures at OPC, PITAC with cisplatin, oxaliplatin and doxorubicin for intrapleural administration is expected to be well tolerated with a minimal of nausea, subcutaneous emphysema and transient chest pains.
Study: NCT05485467

Intervention type: DIAGNOSTIC_TEST
Intervention: coronary CT angiography
Description: Coronary CT angiography will be performed on multislice Siemens Somat Force CT scanner
Study: NCT05518682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lenire bimodal stimulation device
Description: The sound and tongue stimulus parameters such as stimulus rate, stimulus intensity, and the timing relationship between the auditory and somatosensory stimulus events are grouped into stimulation Parameter Sets (PS). PS1 is used during the first 6-weeks of stimulation and PS4 is used during the second 6-weeks of stimulation, similar to what is routinely used for tinnitus individuals in Europe.
Study: NCT06414694

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Oral Challenge
Description: Direct oral challenge to penicillin at a goal dose of 45 mg/kg given in a 10%/90% dose
Study: NCT06204874

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency ablation
Description: See left.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham ablation
Description: See left.
Study: NCT06156618

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate
Description: The proposed study is part of a PhD educational project and will be a double blind, randomised design, crossover trial for the effect of nitrate supplement on healthy control and people with dental erosion (PwDE). This study aims to explore the effect of nitrate supplement on oral microbiome in WMS and SP and its impact on blood pressure and arterial stiffness in healthy controls and PwDE.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate
Description: The proposed study is part of a PhD educational project and will be a double blind, randomised design, crossover trial for the effect of nitrate supplement on healthy control and people with dental erosion (PwDE). This study aims to explore the effect of nitrate supplement on oral microbiome in WMS and SP and its impact on blood pressure and arterial stiffness in healthy controls and PwDE.
Study: NCT05778344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teletechnology-assisted home-based pulmonary rehabilitation
Description: The accuracy and safety of home-based pulmonary rehabilitation will be checked regularly through technology devices such as smart watch and via videotelephony (or telephone calls if indicated).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teletechnology-assisted home-based pulmonary rehabilitation
Description: The accuracy and safety of home-based pulmonary rehabilitation will be checked regularly through technology devices such as smart watch and via videotelephony (or telephone calls if indicated).
Study: NCT05033873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Universal Exercise Unit Therapy (UEU)
Description: Standing, walk standing, half standing, kneel standing, half kneel standing, quadruped position, three point quadruped , alternative quadruped , transitions, walking all these will be done in Universal Exercise Unit with a standardized protocol regimen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sling Exercise Therapt (SET)
Description: 1. The patient's bilateral knee joints/feet will be suspended by a rope belt, and then the patient's pelvis will be elevated and maintained in supine or lateral position, adding flexion and extension training to lower limb if permitted.~2. In supine or lateral position, with patient's head, trunk and pelvis fixed, the therapist will use appropriate elastic bands to assist patient's limbs to do passive-power assisted-power resistance training in all directions (bending, stretch, outreach, and adduction).~3. The patient's chest and abdomen will be suspended by a wide elastic band, positioned him-self in the prone position with the fulcrum of bilateral elbows and knees, and then the torso swayed in all directions, therapists could assist~4. Target elbow and wrist will be suspended, according to the patient's ability to do passive/active open and close chain movement

Intervention type: OTHER
Group type: OTHER
Intervention: Routine Physical Therapy / Control Group
Description: Control group will receive routine physiotherapy with duration one hour including~* Active and passive joint movement~* Muscle strength training~* Bridging exercises~* Balance training in sitting and standing positions, according to the patients' functional state.~* Weight bearing exercises on affected Limbs
Study: NCT05827432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Field-cycling imaging (FCI)
Description: FCI scan
Study: NCT05175638

Intervention type: GENETIC
Intervention: Gene Expression
Description: the expression of specific CNS enzyme (enolase), proinflammatory cytokines MIF and apoptotic marker caspase-3 in the umbilical blood of infants delivered for Covid positive mothers.

Intervention type: GENETIC
Intervention: Gene Expression
Description: the expression of specific CNS enzyme (enolase), proinflammatory cytokines MIF and apoptotic marker caspase-3 in the umbilical blood of infants delivered for Covid positive mothers.
Study: NCT05748496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief behavioral sleep therapy, sleep hygiene education and mindfulness training
Description: Brief behavioral sleep therapy, sleep hygiene education and mindfulness training using breathing exercises and Yoga Nidra
Study: NCT05491304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Single drug in non-severe group; combined with etoposide±ruxolitinib in severe group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Single drug in non-severe group; combined with etoposide±ruxolitinib in severe group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Single drug in non-severe group; combined with etoposide±ruxolitinib in severe group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Used in severe group combined with etoposide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Used in severe group combined with etoposide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Single drug in non-severe group; combined with etoposide and dexamethasone in severe group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Single drug in non-severe group; combined with etoposide and dexamethasone in severe group.
Study: NCT02238574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: excision or carbondioxide laser evaporation of the mucosal lesion of the oral cavity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: follow up
Description: Intensified outpatient follow up (16 visits in 5 years)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: follow up
Description: Intensified outpatient follow up (16 visits in 5 years)
Study: NCT04788511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial.~Dose gradually escalated from 0.25 mg until target dose. The study will last for approximately 59 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial.~The study will last for approximately 59 weeks.
Study: NCT06367673

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iPSC-NK cells
Description: iPSC-NK cells
Study: NCT05898256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: 10mg/kg administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1 g/m2, administered as an IV infusion within 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m2, administered as an IV infusion over 4 hours
Study: NCT04890925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Support Network (CSN) intervention
Description: The SOAR Community Support Network (CSN) intervention is a multi-pillar, interdisciplinary system platform focused on improving higher order cognitive functions through aerobic exercise, mindfulness meditation, counselling, quality of life tracking, and cognitive exercises. The goal is to improve cognitive functions such as executive function, reasoning, and memory among those experiencing the effects of brain injury. Individually tailored protocol is administered to each participant. Goals are set daily, weekly, and monthly, and accomplishments tracked in a database. The CSN seeks to test and evaluate the success of the program when applied, and tailored, to survivors of brain injury in intimate partner violence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants in this group will receive dose-equivalent usual care based on the findings of a recent survey of the Canadian Rehabilitation Clinicians for concussion management, scoping review and clinical studies. Based on the evidence, usual care in this study will consist of education and aerobic exercises. Education includes information about the injury, recovery, management, nutrition, hydration, sleep, reassurance and goal setting that will be adapted to make appropriate to the population of this study. Aerobics include stationary cycling and treadmill exercises.
Study: NCT04834349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hafnium Oxide-containing Nanoparticles NBTXR3
Description: Given IT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hafnium Oxide-containing Nanoparticles NBTXR3
Description: Given IT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Proton Therapy
Description: Undergo IMPT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT05614154

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypochlorous active substance
Description: Poviodin iyot

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypochlorous active substance
Description: Poviodin iyot
Study: NCT06290674

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave therapy
Description: 2000 shots, 120mJ pulse energy setting, 3 bar pressure, and 15 Hz for 15 minute per session.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Balanced low-calorie diet
Description: 1500 k/cal for 6 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balanced low-calorie diet
Description: 1500 k/cal for 6 weeks
Study: NCT05063799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: pulmonary rehabilitation programs
Study: NCT06146920

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of ctDNA using the F1T after 1 year of immunotherapy
Description: Patients with evidence of disease control after at least 10months of an ICI-based therapy will initially undergo a pre-screen. In patients with successful F1CDx baseline tissue testing whole blood will be collected and evaluated for plasma ctDNA measurement. If there is detectable ctDNA during the pre-screening period, patients will be excluded from enrollment. If there is no detectable ctDNA, patients will be eligible to screen and enroll in the main study.~If enrolled, patients will stop ICI- based treatment and continue with serial ctDNA at pre-specified timepoints. The treating physician will not be blinded to the serial ctDNA results There will be no proscriptive therapeutic measures outlined if ctDNA becomes detectable while on study.
Study: NCT05517837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986421
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT06407596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high intensity laser
Description: 3 times per week, for 9 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tens+us
Description: 5 times per week, total 15 sessions for 3 weeks
Study: NCT05998473

Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic stability measurement
Description: The subject is asked to walk 8 meters 3 times: at free speed, at fast speed, and with large steps.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic stability measurement
Description: The subject is asked to walk 8 meters 3 times: at free speed, at fast speed, and with large steps.
Study: NCT06280625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Replacement of wheat flour by soyflour
Description: The intervention consist in replacing a fraction of wheat flour by soyflour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Replacement of wheat flour by soyflour
Description: The intervention consist in replacing a fraction of wheat flour by soyflour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Replacement of wheat flour by soyflour
Description: The intervention consist in replacing a fraction of wheat flour by soyflour
Study: NCT06385431

Intervention type: OTHER
Intervention: observational study
Description: obeservational study with none intervention
Study: NCT04270201

Intervention type: OTHER
Intervention: Saliva collection
Description: Saliva collection

Intervention type: OTHER
Intervention: Saliva collection
Description: Saliva collection
Study: NCT05367232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-033 tablet
Description: Administered orally, once a day, 28 days per cycle
Study: NCT04771949

Intervention type: DIAGNOSTIC_TEST
Intervention: Full periodontal chart
Description: A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.

Intervention type: OTHER
Intervention: Questionnaires
Description: After the periodontal chart, patients will be administered the italian version of 4 questionnaires regarding:~1. Adherence to Mediterranean Diet (Gnagnarella et al. 2018);~2. International Physical Activity Questionnaire (IPAQ) (Mannocci et al. 2010);~3. Pittsburgh Sleep Quality Index (PSQI) (Curcio et al. 2013);~4. Italian Perceived Stress Scale (Fossati, 2010).
Study: NCT03548246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Daily oral abiraterone acetate for 2 years. The dose will be specified based on pharmacodynamic data from Phase 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo for 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone will be administered at a starting dose of 7-9 mg/M2/d and adjusted as necessary based on 17-hydroxyprogesterone and ACTH levels.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone will be administered at a starting dose of 7-9 mg/M2/d and adjusted as necessary based on 17-hydroxyprogesterone and ACTH levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: Fludrocortisone will be administered at the dose the subject was taking a study entry and adjusted as necessary to keep plasma renin in the high normal range.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fludrocortisone
Description: Fludrocortisone will be administered at the dose the subject was taking a study entry and adjusted as necessary to keep plasma renin in the high normal range.